Quantbot Technologies LP Invests $1.23 Million in Progyny, Inc. $PGNY

Quantbot Technologies LP bought a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 42,486 shares of the company’s stock, valued at approximately $1,225,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PGNY. Caitong International Asset Management Co. Ltd purchased a new position in shares of Progyny during the fourth quarter worth $25,000. Hantz Financial Services Inc. lifted its stake in Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after acquiring an additional 742 shares in the last quarter. Quarry LP lifted its stake in Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after acquiring an additional 3,427 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in Progyny during the 2nd quarter valued at about $77,000. Finally, New Age Alpha Advisors LLC acquired a new position in Progyny in the 4th quarter valued at about $94,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Activity

In related news, insider Geoffrey Clapp sold 1,530 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total value of $39,137.40. Following the transaction, the insider owned 59,117 shares of the company’s stock, valued at $1,512,212.86. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Mark S. Livingston sold 2,517 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $25.50, for a total value of $64,183.50. Following the completion of the sale, the chief financial officer owned 74,688 shares in the company, valued at approximately $1,904,544. This represents a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,563 shares of company stock valued at $351,968 over the last quarter. Company insiders own 9.90% of the company’s stock.

Wall Street Analyst Weigh In

PGNY has been the topic of a number of recent research reports. Truist Financial boosted their price target on shares of Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Wall Street Zen lowered shares of Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. BTIG Research raised their price target on shares of Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Citigroup reissued an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Finally, Leerink Partners set a $38.00 price objective on Progyny in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.91.

Progyny Stock Performance

Shares of Progyny stock opened at $25.82 on Wednesday. Progyny, Inc. has a one year low of $16.10 and a one year high of $33.06. The company has a market cap of $1.98 billion, a PE ratio of 28.07, a P/E/G ratio of 1.85 and a beta of 1.01. The business has a 50-day simple moving average of $29.08 and a 200-day simple moving average of $23.55.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same quarter last year, the company earned $0.19 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, sell-side analysts predict that Progyny, Inc. will post 1.19 earnings per share for the current fiscal year.

Progyny declared that its board has approved a share repurchase plan on Tuesday, May 26th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 10.3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.